The Stanford Cancer Institute Office of Cancer Health Equity is dedicated to fostering and strengthening partnerships that improve research, education, and community outreach and engagement to reduce the cancer burden and cancer disparities.
A new artificial intelligence tool developed at Stanford Medicine combines data from medical images with text to predict cancer prognoses and treatment responses.
Reena Thomas, MD, PhD, explains why glioblastoma, and brain cancer, can be challenging to treat and what innovations may help improve patients’ quality of life.
Stanford’s Department of Epidemiology & Population Health and the Stanford Cancer Institute launched an innovative new National Cancer Institute (NCI)-funded predoctoral T32 training program in cancer genetic epidemiology.
Christina Curtis, PhD, MSc, is the recipient of the 2024 American Association of Cancer Research Outstanding Investigator Award for Breast Cancer Research and the Susan G. Komen Brinker Award for Scientific Distinction in Basic Science. She is the...
Researchers used a new screening technique to identify genes involved in heart cell damage during a common chemotherapy treatment. They also found a drug that may be able to prevent it.
Stanford is proud to have 32 scientists presenting oral abstracts, educational sessions, and workshops at the 2024 American Society of Hematology Annual Meeting, along with many poster presentations.
CAR-T cells show promise against pediatric diffuse midline gliomas, brain and spinal cord tumors that are among the deadliest cancers, a Stanford Medicine trial found.
A promising Stanford Medicine treatment for deadly pediatric brain and spinal cord cancers received a Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration to expedite the approval process. By expediting...
A clinical trial investigating a promising blood cancer therapy treated its first patient in August 2024 after receiving fast-track activation from the Stanford Cancer Institute in March 2024.
Tiny circles called ecDNA are critical in cancer development and drug resistance. An international Stanford Medicine-led team publishes landmark studies detailing new findings and potential therapies.
Advancements in lung cancer care are improving individual patient outcomes and addressing the broader challenges of genetic risk factors and health disparities.
The Junior Faculty Forum fosters a culture of collaboration and support for early-career cancer researchers in basic, translational, clinical, and population sciences.
Blood tests for colorectal cancer are an option for patients who would otherwise not be screened, but they are not as effective as colonoscopies or stool tests, a Stanford Medicine-led study found.
Stanford Cancer Institute members Allison Kurian, MD, MSc and Jennifer Caswell-Jin, MD, received a $3.5 million legacy gift to launch the Bright Pink Preventive Risk Outreach And Cascade Testing Program.
Stanford Cancer Institute member Frederick Dirbas, MD, speaks about the intersection of surgery and current radiation therapy treatment for breast cancer and the promise of more efficient radiation therapy with fewer side effects.
While some people with cancer have pre-existing disabilities, most patients are newly disabled as a result of their cancer diagnosis and encounter unique challenges related to their treatments.
Ten percent of childhood cancers are associated with a cancer predisposition syndrome caused by mutations to genes that prevent tumor growth or that drive cell growth and division.
One of the Stanford Cancer Institute’s core values is empowering the next generation of cancer scientists to find innovative solutions that improve patient outcomes. To uphold this value, we offer robust support to students, residents, fellows, and...
An increased understanding of the underlying mechanisms of cancer, cutting-edge technologies, and a seismic cultural shift toward a collaborative team science approach are helping researchers develop novel cancer drugs.
The emerging field of spatial biology holds promise in helping scientists gain an in-depth understanding of the tumor microenvironment and better predict patient outcomes.
In an early Stanford Medicine study, CAR-T cell therapy helps some with intractable lymphoma, but those who relapse have few options. Modifying the therapy's molecular target improved response.
Developing safe and effective allogeneic CAR-T cell therapies has been a long-standing focus for Stanford Cancer Institute member, Melody Smith, MD, MS
The artificial intelligence technology can be trained by pathologists, giving them personalized assistance in identifying cells that might indicate diseases such as cancer or endometritis.
In April, the FDA warned of risk of secondary cancers in people receiving CAR-T cell therapy. A large Stanford Medicine study finds the risk is low and not related to the CAR-T cells.
A lack of disclosure compounded by insufficient sexual orientation and gender identity data collection by providers can lead to a myriad of challenges in prostate cancer treatment.
The professor of dermatology and genetics was honored with the 2024 Lurie Prize for his studies into the role of long noncoding RNA in health and disease.
In a finding that vastly expands the understanding of tumor evolution, researchers discover genetic biomarkers that can predict the breast cancer subtype a patient is likely to develop.
Pamela Herena, director of clinical operations at the SCI Clinical Trials Office, shares her insight into the challenges and rewards of being an oncology nurse.
Stanford scientists illuminate the relationship between adoptively transferred T cells and macrophages and how two immunotherapies may work together to increase their tumor-fighting capabilities.
Thanks to the partnership with Stanford’s Advanced Melanoma Program and Blood and Marrow Transplantation (BMT) & Cellular Therapy Program, Stanford treated the first patient in the world with the newly approved TIL therapy.
The FDA recently approved the first cell-based therapy - widely used in treating blood cancers - for solid tumors. Stanford Medicine treated the first patient with advanced melanoma.
Within the past couple of decades, the field of oncology has witnessed a shift to more curative treatments for patients with lung cancer, with radiation being a key factor in this new trajectory.
Cancer scientists at Stanford and the Children’s Hospital of Philadelphia (CHOP) identified a protein, FOXO1, that improves the survival and function of CAR-T cells, which may lead to more effective CAR-T cell therapies and could potentially expand...
Artificial intelligence algorithms powered by deep learning improve skin cancer diagnostic accuracy for doctors, nurse practitioners and medical students in a study led by the Stanford Center for Digital Health.
TRACeR platforms more accurately recognize a wide variety of surface proteins expressed by cancer cells that make them easier to target with the body’s own immune system.
Researchers used artificial intelligence to predict the activity of thousands of genes in tumors based on routinely collected images of tumor biopsies. It could guide treatment without costly genomic tests.
A longtime caretaker of very ill patients, clinical professor, Bryant Lin, MD, a primary care physician, educator and researcher, is now discovering what it's like to be on the opposite end of that arrangement.
The Office of Communication & Public Affairs is dedicated to sharing School of Medicine news with the media and helping journalists secure expert interviews, photographs and rich media for stories on medicine and health care.
